<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC6925075/table_2" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 2</label>
  <p>The Coalition for Epidemic Preparedness Innovations (CEPI) funded projects (as of November 2019)</p>
 </caption>
 <thead>
  <tr>
   <th colspan="1" rowspan="1" id="0-0-.">Partner</th>
   <th colspan="1" rowspan="1" id="0-1-.">Disease</th>
   <th colspan="1" rowspan="1" id="0-2-.">CEPI funding</th>
   <th colspan="1" rowspan="1" id="0-3-.">Technology platform</th>
   <th colspan="1" rowspan="1" id="0-4-.">Development phase</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td rowspan="3">Janssen Vaccines and University of Oxford</td>
   <td>Lassa</td>
   <td rowspan="3">US$19.0 million</td>
   <td rowspan="3">Recombinant virus</td>
   <td>Preclinical</td>
  </tr>
  <tr>
   <td>MERS-CoV</td>
   <td>Phase I</td>
  </tr>
  <tr>
   <td>Nipah</td>
   <td>Preclinical</td>
  </tr>
  <tr>
   <td rowspan="2">Profectus BioSciences, Emergent BioSolutions, and PATH</td>
   <td>Lassa</td>
   <td>US$36.0 million</td>
   <td>Recombinant virus</td>
   <td>Preclinical</td>
  </tr>
  <tr>
   <td>Nipah</td>
   <td>US$25.0 million</td>
   <td>Protein subunit</td>
   <td>Preclinical</td>
  </tr>
  <tr>
   <td>International AIDS Vaccine Initiative (IAVI)</td>
   <td>Lassa</td>
   <td>US$54.9 million</td>
   <td>Recombinant virus</td>
   <td>Preclinical</td>
  </tr>
  <tr>
   <td>IDT Biologika</td>
   <td>MERS-CoV</td>
   <td>US$36.0 million</td>
   <td>Recombinant virus</td>
   <td>Phase I</td>
  </tr>
  <tr>
   <td rowspan="3">Themis Bioscience</td>
   <td>Lassa</td>
   <td rowspan="3">US$58.5 million</td>
   <td rowspan="3">Recombinant virus</td>
   <td>Phase I</td>
  </tr>
  <tr>
   <td>MERS-CoV</td>
   <td>Preclinical</td>
  </tr>
  <tr>
   <td>Chikungunya</td>
   <td>Phase III</td>
  </tr>
  <tr>
   <td>University of Tokyo</td>
   <td>Nipah</td>
   <td>US$31.0 million</td>
   <td>Recombinant virus</td>
   <td>Phase I</td>
  </tr>
  <tr>
   <td rowspan="2">Inovio Pharmaceuticals</td>
   <td>Lassa</td>
   <td rowspan="2">US$56.0 million</td>
   <td rowspan="2">DNA</td>
   <td>Preclinical</td>
  </tr>
  <tr>
   <td>MERS-CoV</td>
   <td>Phase II</td>
  </tr>
  <tr>
   <td>Colorado State University</td>
   <td>Rift Valley fever</td>
   <td>US$9.5million</td>
   <td>Attenuated virus</td>
   <td>Preclinical</td>
  </tr>
  <tr>
   <td>Wageningen Bioveterinary Research</td>
   <td>Rift Valley fever</td>
   <td>US$12.5 million</td>
   <td>Attenuated virus</td>
   <td>Phase I</td>
  </tr>
  <tr>
   <td>Valneva</td>
   <td>Chikungunya</td>
   <td>US$23.4 million</td>
   <td>Attenuated virus</td>
   <td>Phase I</td>
  </tr>
  <tr>
   <td>Public health vaccines</td>
   <td>Nipah</td>
   <td>US$43.6 million</td>
   <td>Recombinant virus</td>
   <td>Preclinical</td>
  </tr>
  <tr>
   <td rowspan="3">Imperial College London</td>
   <td>Marburg</td>
   <td rowspan="3">US$8.4 million</td>
   <td rowspan="3">RNA</td>
   <td rowspan="3">Preclinical</td>
  </tr>
  <tr>
   <td>Influenza</td>
  </tr>
  <tr>
   <td>Rabies</td>
  </tr>
  <tr>
   <td rowspan="3">CureVac</td>
   <td>Lassa</td>
   <td rowspan="3">US$34.0 million</td>
   <td rowspan="3">RNA</td>
   <td rowspan="3">
    <p>Preclinical</p>
    <p>Phase I</p>
   </td>
  </tr>
  <tr>
   <td>Rabies</td>
  </tr>
  <tr>
   <td>Yellow fever</td>
  </tr>
  <tr>
   <td rowspan="3">University of Queensland</td>
   <td>MERS-CoV</td>
   <td rowspan="3">US$10.6 million</td>
   <td rowspan="3">Recombinant protein</td>
   <td rowspan="3">Preclinical</td>
  </tr>
  <tr>
   <td>Influenza</td>
  </tr>
  <tr>
   <td>Respiratory syncytial virus</td>
  </tr>
 </tbody>
</table>
